Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 805.86M | 1.21B | 1.20B | 1.11B | 937.69M |
Gross Profit | 516.49M | 875.89M | 913.53M | 854.54M | 680.76M |
EBITDA | 169.32M | 340.65M | 366.96M | 360.99M | 349.78M |
Net Income | 124.99M | 277.82M | 307.72M | 322.36M | 283.37M |
Balance Sheet | |||||
Total Assets | 3.47B | 3.65B | 3.41B | 3.00B | 1.54B |
Cash, Cash Equivalents and Short-Term Investments | 1.89B | 2.10B | 1.72B | 1.74B | 690.12M |
Total Debt | 866.44K | 1.75M | 1.31M | 1.23M | 1.85M |
Total Liabilities | 644.39M | 770.33M | 690.07M | 530.58M | 460.41M |
Stockholders Equity | 2.82B | 2.88B | 2.72B | 2.47B | 1.08B |
Cash Flow | |||||
Free Cash Flow | -51.07M | 478.47M | 16.10M | -34.62M | 236.68M |
Operating Cash Flow | -1.90M | 511.71M | 41.01M | 164.79M | 260.68M |
Investing Cash Flow | 55.84M | -81.56M | ― | ― | ― |
Financing Cash Flow | -183.14M | -121.33M | ― | 1.07B | -11.88M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
67 Neutral | HK$8.18B | 41.00 | 4.39% | 0.07% | -32.05% | -54.47% | |
52 Neutral | $7.61B | 0.11 | -63.03% | 2.07% | 16.35% | 0.29% | |
― | €592.80M | ― | -10.43% | ― | ― | ― | |
― | €800.37M | 59.80 | 3.22% | 0.54% | ― | ― | |
75 Outperform | HK$6.93B | 22.05 | 10.92% | 0.18% | 20.19% | 45.54% | |
73 Outperform | HK$5.12B | 11.61 | 8.40% | 0.17% | 12.41% | ― | |
69 Neutral | HK$8.42B | 36.51 | 6.49% | ― | 0.87% | -18.05% |
Beijing Chunlizhengda Medical Instruments Co., Ltd. has released supplemental information regarding the remuneration of its chief executive, who is not a director, for the years 2022, 2023, and 2024. The announcement clarifies the emoluments paid, highlighting that no inducement or compensation for loss of office was provided, nor were any emoluments waived by the chief executive in these years. This disclosure provides transparency in the company’s financial reporting and may impact stakeholder perceptions regarding executive compensation practices.
The company recently held an Adjourned H Shareholders’ Class Meeting on July 7, 2025, in Beijing, which was convened by the board of directors and chaired by Ms. Shi Wenling. The meeting adhered to the legal and regulatory requirements of the PRC and the Hong Kong Stock Exchange, with voting conducted by a registered poll. All directors attended, either in person or by phone, and there were no restrictions on shareholder voting. The meeting saw attendance from shareholders holding 11.6541% of the total H Shares.
Beijing Chunlizhengda Medical Instruments Co., Ltd. announced the results of resolutions passed at their 2024 annual general meeting, including the declaration of a final ordinary cash dividend of RMB 0.49 per 10 shares for the financial year ending December 31, 2024. The dividend, approved on June 26, 2025, will be paid in Hong Kong dollars at a rate of HKD 0.5364 per 10 shares, with specific withholding tax rates applied based on shareholder residency. This announcement reflects the company’s commitment to returning value to its shareholders and may impact its financial performance and investor relations positively.
Beijing Chunlizhengda Medical Instruments Co., Ltd. held its 2024 Annual General Meeting and A Shareholders’ Class Meeting on June 26, 2025, where all proposed resolutions were passed. The meeting was conducted in compliance with relevant regulations, and voting was overseen by WUYIGE Certified Public Accountants LLP. Key shareholders abstained from voting on certain resolutions, and there were no stated intentions to oppose any resolutions.
Beijing Chunlizhengda Medical Instruments Co., Ltd. announced the adjournment of its H Shareholders’ Class Meeting due to insufficient voting rights participation. The meeting, initially scheduled for June 26, 2025, will now be held on July 7, 2025. This rescheduling ensures compliance with the company’s articles of association, allowing for adequate shareholder representation and decision-making.
Beijing Chunlizhengda Medical Instruments Co., Ltd. has announced a class meeting for H shareholders to discuss a special resolution regarding the repurchase of H Shares. The proposed mandate would allow the board to repurchase up to 10% of the total H Shares, excluding treasury shares, based on market conditions and company needs. This move could potentially impact the company’s share capital structure and market positioning, reflecting strategic financial management to enhance shareholder value.
Beijing Chunlizhengda Medical Instruments Co., Ltd. has announced the schedule for its 2024 Annual General Meeting, set for June 26, 2025. Key resolutions to be discussed include the approval of the 2024 profit distribution plan, remuneration for directors and supervisors for 2025, and the re-appointment of auditors. Additionally, a special resolution will consider granting the board a mandate to repurchase up to 10% of its H Shares, reflecting the company’s strategic financial management and commitment to shareholder value.
Beijing Chunlizhengda Medical Instruments Co., Ltd. announced the resignation of two senior management members, Mr. Zhai Zhiyong and Ms. Li Yumei, due to personal reasons. Both will continue to serve the company in other capacities. The company appointed Ms. Lu Hongyue as the new Chief Financial Officer, effective immediately, to ensure continuity in financial management. This leadership change is expected to support the company’s ongoing financial strategies and operations.
Beijing Chunlizhengda Medical Instruments Co., Ltd. has released its unaudited financial results for the first quarter of 2025, in compliance with the Chinese Accounting Standards for Business Enterprises. The report, available in both Chinese and English, highlights the company’s financial performance for the three months ending March 31, 2025. Stakeholders are advised to consider potential investment risks as the data has not been audited.